EGFR and non-small cell lung carcinoma: The link between TP53 mutations and targeted therapy response should be considered a starting point for new investigations, and further studies are needed to investigate these mechanisms to effectively predict responsiveness and survival; thus, better tailoring targeted therapy for EGFR-NSCLC patients.